Citations per year, relative to R Bucovec R Bucovec (= 1×)
peers
A Ardizzoia
Countries citing papers authored by R Bucovec
Since
Specialization
Citations
This map shows the geographic impact of R Bucovec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Bucovec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Bucovec more than expected).
This network shows the impact of papers produced by R Bucovec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Bucovec. The network helps show where R Bucovec may publish in the future.
Co-authorship network of co-authors of R Bucovec
This figure shows the co-authorship network connecting the top 25 collaborators of R Bucovec.
A scholar is included among the top collaborators of R Bucovec based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with R Bucovec. R Bucovec is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
11 of 11 papers shown
1.
Cerea, Giulio, Massimo Vaghi, A Ardizzoia, et al.. (2003). Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.. PubMed. 23(2C). 1951–4.87 indexed citations
2.
Lissoni, Paolo, et al.. (2003). Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients.. PubMed. 17(1). 73–5.6 indexed citations
3.
Lissoni, Paolo, Fabio Malugani, R Bucovec, et al.. (2002). Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1.. PubMed. 15(2). 140–4.88 indexed citations
4.
Lissoni, P., Massimo Vaghi, Luca Fumagalli, et al.. (2002). Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.. PubMed. 22(2B). 1061–4.19 indexed citations
5.
Lissoni, Paolo, Elena Fumagalli, Fabio Malugani, et al.. (2002). Stimulation of IL-12 secretion by GM-CSF in advanced cancer patients.. PubMed. 15(2). 163–5.3 indexed citations
6.
Lissoni, Paolo, R Bucovec, Fabio Malugani, et al.. (2002). A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.. PubMed. 22(2B). 1131–4.19 indexed citations
Lissoni, Paolo, F Brivio, Gabriele Fumagalli, et al.. (2001). Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease.. PubMed. 14(4). 275–7.33 indexed citations
9.
Lissoni, Paolo, Franco Rovelli, Fabio Malugani, et al.. (2001). Anti-angiogenic activity of melatonin in advanced cancer patients.. PubMed. 22(1). 45–7.138 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.